IP Library Granted Patent US 10,364,283
Granted Patent B2
US 10,364,283 · App. 14/697,759 · Granted Jul 30, 2019

Collagen hydrolysate and use thereof

Inventors: Steffen Oesser (Glücksburg, DE); Monika Giesen-Wiese (Höchst, DE); Hans-Ulrich Frech (Weinheim, DE); Stephan Hausmanns (Heidelberg, DE)
Assignee: GELITA AG
C07K14/78A23J3/342A23L33/18A61K35/32A61K38/014A61K45/06A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,364,283
App. No.
14/697,759
Granted
Jul 30, 2019
Kind
B2
Abstract

The present invention relates to a collagen hydrolysate which is produced by enzymatic hydrolysis of type-B bone gelatin, wherein the collagen hydrolysate is formed from peptides of which at least 50% by weight, in particular at least 70% by weight have a molecular weight of 1,500 Da to 3,500 Da, and which have a mean molecular weight in the range from 4,000 Da to 8,000 Da, in particular in the range from 4,500 Da to 6,000 Da. The invention also relates to the use of this collagen hydrolysate as an active ingredient to maintain and/or improve the health of the bones, in particular to prevent and/or treat osteoporosis. The invention further relates to a nutritional supplement which comprises the collagen hydrolysate.

Claims (13)

1. A collagen hydrolysate which is produced by enzymatic hydrolysis of type-B bone gelatin, wherein the collagen hydrolysate is formed from hydrolyzed collagen peptides of which at least 50% by weight have a molecular weight of 1,500 Da to 13,500 Da, and which have a weight average molecular weight in the range from 4,000 Da to 8,000 Da, wherein the bone gelatin is produced by alkaline breakdown of collagen from bones of vertebrates.

2. The collagen hydrolysate according to claim 1 , wherein the bone gelatin has an isoelectric point of below 5.5.

3. The collagen hydrolysate according to claim 1 , wherein the peptides have an overall amidation level of glutamine groups and/or glutamic acid groups and of asparagine groups and/or aspartic acid groups of less than 15%.

4. The collagen hydrolysate according to claim 1 , wherein a 20% by weight aqueous solution of the collagen hydrolysate has a viscosity at 25° C. of more than 5 mPa·s.

5. The collagen hydrolysate according to claim 1 , wherein the collagen hydrolysate has an ammonium, sulphate and phosphate content of less than 300 ppm each.

6. The collagen hydrolysate according to claim 1 , wherein the collagen hydrolysate is produced by hydrolysis of the gelatin with a neutral endoprotease from Bacillus subtilis.

7. The collagen hydrolysate according to claim 6 , wherein the collagen hydrolysate is produced through the action of the endoprotease at a temperature of 40° C. to 60° C. over a period of 20 min to 40 min.

8. The collagen hydrolysate according to claim 1 , wherein the collagen hydrolysate is a nutritional supplement.

9. A nutritional supplement comprising the collagen hydrolysate of claim 1 and one or more prebiotics.

10. The nutritional supplement according to claim 9 , wherein the prebiotic or prebiotics is/are selected from oligosaccharides and/or polysaccharides.

11. The nutritional supplement according to claim 9 , further comprising one or more soluble calcium salts.

12. The nutritional supplement according to claim 9 , further comprising one or more vitamins which are selected from vitamin C, vitamin D, vitamin D 3 , vitamin E, vitamin K and the metabolites thereof.

13. The nutritional supplement according to claim 9 , further comprising one or more minerals which are selected from the group consisting of fluorine salts, potassium salts and magnesium salts.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2015
From: OESSER, STEFFEN; GIESEN-WIESE, MONIKA; FRECH, HANS-ULRICH; HAUSMANNS, STEPHAN
To: GELITA AG
Reel/Frame 035521/0807 →
Priority Claims (1)
DE 10 2012 110 612 · Nov 6, 2012 · national
Continuity (2)
Continuation PCTEP2013072894 · Nov 4, 2013
Related Publication 20150232534A1 · Aug 20, 2015
Cited By (2)
US 12,520,859 US 12,528,857